股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳國際控股有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00152 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 1 | HKD | | 3,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,000,000,000 | HKD | | 1 | HKD | | 3,000,000,000 | 本月底法定/註冊股 ...

Core Viewpoint - Shenzhen has established the first national ship registration comprehensive service platform, the Shenzhen International Ship Registration Service Center, to enhance its international shipping service capabilities and support the development of the Greater Bay Area [1][2]. Group 1: Establishment and Purpose of the Center - The Shenzhen International Ship Registration Service Center was officially launched on December 29, marking a significant step in the city's efforts to develop its shipping industry and innovate reforms [1]. - The center aims to fill the gap in international ship quality assurance and maritime facility registration, serving as a high-level platform to gather global resources and support regional development [1][2]. Group 2: Policy Background and Reforms - The establishment of the center aligns with national policies, including the 2020 deployment of comprehensive reform pilot programs in Shenzhen, which included the reform of the international ship registration system [2]. - The 2021 plan for the Qianhai-Shenzhen-Hong Kong Modern Service Industry Cooperation Zone expanded this reform to include international ship registration and supporting system reforms [2]. Group 3: Innovations and Future Plans - The new "non-stop operation certificate transfer" innovation allows for quicker ship registration processes, significantly reducing the time required for ship re-registration from over 20 days to a much shorter period [2]. - By December 2024, the "China Qianhai" ship registry is expected to grow rapidly, with plans to add 18 ships, totaling 20 vessels with a gross tonnage of 580,000 tons and a value of 5.8 billion yuan, positioning it among the top three in the country [3].

Core Viewpoint - Shenzhen International (00152.HK) has received approval from the Longhua District government for the second phase of the South China Transformation Project, marking a significant step in its development strategy [1] Group 1: Project Approval and Development - The company has obtained development rights for the land plot (02-20-02) designated for the second phase of the South China Transformation Project [1] - The land is classified as Class II residential land, with an area of 25,008 square meters and a planned plot ratio of 5.8 [1] - The company aims to advance the development and construction of high-quality residential projects, ensuring timely sales returns and cash flow [1]

Core Viewpoint - Shenzhen International (00152) has received approval from the Longhua District government for the second phase of the South China Transformation Project, marking a significant step in the company's development strategy [1] Group 1: Project Approval and Development - The land parcel (02-20-02) has been officially approved for development, allowing the company to proceed with land transfer procedures [1] - The land is designated as Class II residential land, covering an area of 25,008 square meters with a planned floor area ratio of 5.8 [1] - The company aims to develop a high-quality demonstration residential project, focusing on timely sales collection and cash flow management [1]

Core Viewpoint - Shenzhen International (00152) has received approval from the Longhua District government for the second phase of the South China Transformation Project, marking a significant step in its development strategy [1] Group 1: Project Approval and Development - The land parcel (02-20-02) has been officially approved for development, allowing the company to proceed with land transfer procedures [1] - The land is designated as Class II residential land, covering an area of 25,008 square meters with a planned plot ratio of 5.8 [1] - The company aims to develop a high-quality demonstration residential project, focusing on timely sales collection and cash flow management [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （於百慕達註冊成立之有限公司） （股份代號：00152） 自願性公告 華南物流園項目一期轉型升級進展 茲提述本公司日期為 2023 年 10 月 31 日、2024 年 12 月 30 日及 2025 年 7 月 25 日的公告（ 「 該 等 公 告 」 ） ，內容有關（其中包括）（1）本集 團就開展華南轉型項目與深圳市龍華區城市更新和土地整備局 、 深 圳 市 龍 華 區 民 治 街 道 辦 事 處 及 市 規 資 局 龍 華 局 簽 訂 了 土 地 整 備 協 議 ， 各 方 同 意 綜 合 採 用 安 排 留 用 土 地 和 貨 幣 補 償 的 方 式 實 施 該 項 目 。 華 南 物 流 公 司 作 為 原 土 地 使 用 權 人 ， 可 在 華 南 物 流 園 內 留 用 面 積 約 108,749 平 方米的留用土地；（2）第一期留用土地（即 02-20-04 號地塊）的相關 安排於 20 ...

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 300 global companies and more than 1,000 innovative products, highlighting China's transition from "technology catch-up" to "innovation leadership" in the medical device industry [1] - The annual innovation results from the National High-Performance Medical Device Innovation Center revealed 11 assessment results, including the "Top 100 Emerging Enterprises" focusing on high-end medical imaging and surgical robots, with 100 companies engaging in 339 industry-academia-research collaborations and undertaking 133 research projects [1] - The assessment introduced three innovation indices focusing on emerging fields such as AI-assisted diagnosis and ophthalmic devices, indicating significant breakthroughs in globally pioneering products like vascular interventional surgical robots and critical materials in "bottleneck" areas [1] Group 2 - The report "Trends in Medical Equipment Patents in China (2025)" indicated that by 2025, China will have over 2.8 million medical equipment patent applications, maintaining the global lead with a 34.1% share, and a year-on-year growth of 3.2%, with a ten-year compound growth rate of 15.5%, both double the global average [2] - Shenzhen contributed 140,000 patent applications, accounting for 43.1% of Guangdong Province's total of 325,000 applications, showcasing the city's significant role in medical device innovation [2] - Experts noted that the medical device industry has shifted from imitation to independent innovation, achieving a level of development comparable to global standards, with future devices expected to integrate various technologies for smarter, personalized, and more active solutions to health and disease [2]

Group 1: Airline Industry - Goldman Sachs forecasts that international demand will rise while supply constraints persist, leading to an expected return on equity (ROE) of 22% for airlines by 2027, surpassing the industry cycle average [1] - Despite risks associated with Japan in the first half of the year, the outlook for airline stocks remains positive, with expectations for further increases in ticket prices; preferred stocks include Air China H-shares and China Eastern Airlines A-shares [1] Group 2: Container Shipping - The recovery in supply has led Goldman Sachs to adopt a more cautious stance on container shipping, predicting a compression in industry profit margins [1] - New ship orders this year have exceeded expectations, resulting in an order-to-existing capacity ratio of 33% [1] - Potential reopening of the Red Sea may pose additional downside risks, potentially releasing about 10% of effective capacity, which could lead to cash consumption issues for COSCO Shipping Holdings [1] Group 3: Oil Tankers - Goldman Sachs maintains an optimistic outlook for oil tankers, expecting spot freight rates to rise further during the ongoing upward cycle in 2026 [1] - The process of China's oil reserve buildup may take up to a year, longer than the market's expectation of three months, while effective capacity is predicted to grow by only 1% [1] - COSCO Shipping Energy is expected to benefit due to its significant exposure to oil tankers and the Chinese import market [1]

Group 1 - The 2025 Shenzhen International High-Performance Medical Device and Innovative Pharmaceutical Exhibition showcased over 1,000 innovative products from more than 300 leading global pharmaceutical and medical device companies, covering the latest achievements in high-end medical devices, innovative drugs, and AI applications [1] - The exhibition featured ten major exhibition areas, including medical imaging, emergency rescue, rehabilitation, and artificial intelligence, creating a comprehensive platform for display, communication, and collaboration within the pharmaceutical and medical device industry [1] - The event was organized by the China Medical Equipment Association, the National High-Performance Medical Device Innovation Center, and the Shenzhen Medical Device Industry Association [1] Group 2 - The exhibition highlighted advancements in future medical technologies, such as robotic surgery, advanced imaging equipment, brain-machine interfaces, and AI-assisted rehabilitation tools, demonstrating the potential of these innovations [2] - Notable products included the multi-port and single-port laparoscopic surgical robots from Qingfeng Medical, and an AI-based drug-device research public service platform from Particle Technology, which significantly reduces traditional research and development timelines [2] - Major companies like Mindray and Siemens showcased their cutting-edge medical equipment, emphasizing the clinical applications and enhanced imaging capabilities of their products [2] Group 3 - The pharmaceutical and medical device industry in Shenzhen has seen continuous growth, with an industry output value reaching 157.6 billion yuan in 2024, including over 102.8 billion yuan from medical devices, maintaining the top position in the country for ten consecutive years [3] - Shenzhen has nurtured 35 listed companies and 143 enterprises with an output value exceeding 100 million yuan in the pharmaceutical and medical device sector, with leading firms such as Mindray and Xintai emerging in various market segments [3] - The exhibition served as a platform for the release of significant collaborations and innovations, including a $1.64 billion strategic partnership between Pruijin and Kite for in vivo CAR-T therapies, showcasing the global push for cell therapy technologies [3]

2026深圳国际复合材料工业技术展览会 各类树脂（不饱和/环氧/乙烯/酚醛等）各类纤维及增强材料（玻纤/碳纤/玄武岩纤维/芳纶/天然纤维等）胶黏剂、各种助剂、填料、色料及预混料、预浸料、 以及上述原材料的生产、加工和处理设备等； 复合材料生产技术与设备： 时间：2026年6月10-12日 地点：深圳国际会展中心 展会简介： 欢迎参加"2026深圳国际复合材料工业技术展览会"本届展会以"科技创新、引领未来"为主题，将于2026年6月10-12日在深圳国际会展中心隆重举办，本届展 览会将继承和发扬往届展会高规格、大规模、专业化的标准水平特色提高服务质量，扩大宣传力度，吸引更多国内外厂商参展，同时也将更广泛地组织国内 外专业观众参观。展会集结国内外著名企业参展，将集中展示原材料及其生产设备、复合材料生产技术和设备、最终制品及应用、复合材料质量控制与检 测、材料的机械加工设备、复合材料及其他制品的节能，全面覆盖材料制造、生产管理、喷射缠绕、模压、环保回收相关产业链的创新研发。市场、高管及 采购决策者莅临现场共促商贸还邀请各大专院校、科研单位、相关行业协会、新闻媒体、投资贸易机构人士参观。进一步突出专业性、权威性和国际 ...